NEW YORK, March 25 - The protein chip market is "poised for enormous growth" over the next four years, a recent industry study has found.
The three-month study, called Protein Biochips: On the Threshold of Success, predicts that sales of protein chips will exceed $700 million in 2006, a 10-fold increase from the $76 million in sales the industry recorded one year ago.
"With at least 25 companies either selling protein biochips today or preparing to enter the market within the next two years, sales in this industry are poised for enormous growth," according to BioInsights, which conducted the study.
In its report, released on Monday, BioInsights also compared interaction biochips with capture biochips, and pre-fabricated protein biochips with tools used to assemble biochips.
The report also examined the demand for protein chips in drug discovery, drug validation, therapeutic development, pre-clinical and clinical trials, and diagnostics.
Companies, academic centers, and government labs highlighted in the report include Archemix, Aspira Biosystems, Biacore, BioForce Nanosciences, BioInvent International, Biosite, Cambridge Antibody Technology, Ciphergen, Clontech, CombiMatrix, GeneScan, Glaucus Proteomics, HTS Biosystems, Harvard Medical Institute of Proteomics, Jerini, Large Scale Biology, Lawrence Livermore National Laboratory, NextGen Sciences, Packard BioScience, Phylos, Prolinx, Protagen, Protometrix, Randox, SomaLogic, TeleChem International, Van Andel Research Institute, Zeptosens, and Zyomyx.
In an interview with GenomeWeb, Felicia Gentile, president of Redwood City, Calif.-based BioInsights, said that although protein chips and DNA chips are complementary tools, "the reality is that people are now interested in the business end [of research]. And the proteins are the business end now."
She stressed, however, that this doesn't mean that researchers will be abandoning their DNA chips any time soon. "I do see more of an emphasis in the proteomics, but I don't see the DNA chip completely going away," said Gentile. "But I do think there will be less emphasis on them" in the coming months and years.